摘要
Symplicity-3 hypertension(HTN) was a recently completed clinical trial that was assumed to be the basis for the approved use of renal artery denervation for the treatment of resistant hypertension in the United States.Dramatic reductions in blood pressure had been reported in two clinical trials(Symplicity-1HTN,-2HTN) carried out in Europe,however Symplicity-3HTN did not show a significant reduction of systolic blood pressure in patients with resistant hypertension 6 mo after renal artery denervation as compared with a sham control.(Denervation group,blood pressure reduction:-14 ± 24,Sham control:-12 ± 26 mm Hg).In this review we discuss several potential explanations for the failure of efficacy of Symplicity-3HTN taking into account basic and clinical factors which could have played a role in the discrepancy between the European and American experience.
Symplicity-3 hypertension(HTN) was a recently completed clinical trial that was assumed to be the basis for the approved use of renal artery denervation for the treatment of resistant hypertension in the United States.Dramatic reductions in blood pressure had been reported in two clinical trials(Symplicity-1HTN,-2HTN) carried out in Europe,however Symplicity-3HTN did not show a significant reduction of systolic blood pressure in patients with resistant hypertension 6 mo after renal artery denervation as compared with a sham control.(Denervation group,blood pressure reduction:-14 ± 24,Sham control:-12 ± 26 mm Hg).In this review we discuss several potential explanations for the failure of efficacy of Symplicity-3HTN taking into account basic and clinical factors which could have played a role in the discrepancy between the European and American experience.
